GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endonovo Therapeutics Inc (OTCPK:ENDV) » Definitions » Forward PE Ratio

Endonovo Therapeutics (Endonovo Therapeutics) Forward PE Ratio : 0.00 (As of Jun. 11, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Endonovo Therapeutics Forward PE Ratio?

Endonovo Therapeutics's Forward PE Ratio for today is 0.00.

Endonovo Therapeutics's PE Ratio without NRI for today is 0.00.

Endonovo Therapeutics's PE Ratio for today is 0.17.


Endonovo Therapeutics Forward PE Ratio Historical Data

The historical data trend for Endonovo Therapeutics's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endonovo Therapeutics Forward PE Ratio Chart

Endonovo Therapeutics Annual Data
Trend
Forward PE Ratio

Endonovo Therapeutics Quarterly Data
Forward PE Ratio

Competitive Comparison of Endonovo Therapeutics's Forward PE Ratio

For the Biotechnology subindustry, Endonovo Therapeutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Endonovo Therapeutics's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Endonovo Therapeutics's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Endonovo Therapeutics's Forward PE Ratio falls into.



Endonovo Therapeutics Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Endonovo Therapeutics  (OTCPK:ENDV) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Endonovo Therapeutics Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Endonovo Therapeutics's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Endonovo Therapeutics (Endonovo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367
Endonovo Therapeutics Inc is an us-based biotechnology company that focuses on the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary square waveform device. It is engaged in developing the Immunotronics platform which is non-implantable, a non-invasive medical device to target inflammatory conditions in vital organs; and the Cytotronics platform which uses Time-Varying Electromagnetic Fields technology for the creation of cell-based therapies. The company generates its revenue through its technology licensing and commercialization activities.
Executives
Alan Brian Collier director, 10 percent owner, officer: CEO 6320 CANOGA AVENUE, 15TH FLOOR, WOODLAND HILLS CA 91367
Michael Scott Mann 10 percent owner, officer: President 6320 CANOGA AVENUE, WOODLAND HILLS CA 91367

Endonovo Therapeutics (Endonovo Therapeutics) Headlines